From: Drug versus vaccine investment: a modelled comparison of economic incentives
Term | Definition |
---|---|
B | Budget threshold (regulator) |
CA _{ ji } | Cost avoided with technology j in year i |
c _{ c } | Annual cost of the disease per cohort before introduction of a new technology |
C _{ ji } | Cost associated with developing and selling technology j in year i |
d | Number of years after launch used for economic evaluations by the manufacturer |
E _{ ji } | Incremental quality-adjusted life-years gained from technology j in year i |
j | Technology indicator(j = 0 for treatment; j = 1 for prevention) |
l | Number of years required to develop technology before launch |
M _{ ji } | Gross margin for technology j in year i |
t | Time horizon in years used for economic evaluation (regulator) |
n _{ c } | Number of cohorts susceptible to the disease |
P _{ ji } | Price of technology j in year i |
Q _{ ji } | Quantity (demand) for technology j in year i |
r _{ m } | Discount rate used by manufacturer to evaluate investment |
r _{ r } | Discount rate used by regulator to evaluate new technologies |
s | Annual probability of children in susceptible cohorts becoming sick |
S _{ ji } | Sales of technology j in year i |
ψ _{ t } ( r ) | Discounting factor in the t^{th} year, if the discount rate is r |